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2 The Journal of Thoracic and Cardiovbjectives: Omega-3 fatty acids exhibit anti-inflammatory, antithrombotic, and
ntiarrhythmic properties. We investigated the extent and underlying mechanism of
rotection conferred by a pre-emptive omega-3 infusion in a model of regional
ardiac ischemia-reperfusion injury.
ethods: New-Zealand White rabbits received either the omega-3 infusion or a
ontrol infusion of 0.9% saline (n  14 in each group). The large marginal branch
f the left coronary artery was occluded for 30 minutes, cardiac function was
ssessed during 3 hours of reperfusion, and infarct size was measured. Pretreatment-
nduced alterations in myocardial membrane fatty acid composition and intramyo-
ardial heat shock protein 72 were additionally assessed (n  5 in each group).
erum markers of myocardial membrane oxidative stress, malonaldehyde and
-isoprostane, were also determined. Results are expressed as means  standard
rror of the mean and significance was tested with analysis of variance.
esults: Pretreatment increased myocardial membrane omega-3 fatty acid content
-fold, from 0.94%  0.07% in controls to 5.38%  0.44% in the omega-3 group
P  .01), and it produced a 225% elevation of levels of heat shock protein 72 (P
.019) before ischemia-reperfusion. This was associated with a 40% reduction in
nfarct size (P  .01). Whereas the reperfusion-induced rise in malonaldehyde
evels was higher with omega-3 pretreatment, 10.2 1.5 mol/L versus 6.1  0.7
mol/L in controls (P  .04), 8-isoprostanes showed a 9-fold reduction, 679  190
g/mL in controls vs 74  45 pg/mL in the omega-3 group (P  .0077).
onclusions: A pre-emptive omega-3 infusion significantly reduces infarct size
hrough the dual mechanisms of upregulation of heat shock protein 72, a key
reconditioning protein, and a dramatic increase in the omega-3 content of myo-
ardial membranes, which appears to facilitate a shift in oxidant ischemia-reperfusion
njury. Further study to optimally shorten the pretreatment regimen for this poten-
ially acceptable infusion will now be pursued.
ore than 25 years have passed since Buckberg and associates1 defined the
benefits of cardioplegia in attenuating myocardial oxygen consumpt
and our understanding of myocardial preservation has moved from
imple paradigm of the balance between supply and demand to tackling the
ultidimensional pathology of ischemia-reperfusion injury. Complex combined
ascular Surgery ● July 2006
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Palve-graft procedures, redo procedures, more diffuse cor-
nary disease, and surgery in those with hypertrophic or
ilated hearts challenge current methods of myocardial pro-
ection with cardioplegia.2 More recently, off-pump surger
otentially limits protection against regional ischemia. The
nfant’s heart appears to be more vulnerable to injury during
urgery,2 in which there has been a shift from palliatio
arlier primary anatomic correction. In all cases, the lack of
hysiologic reserve to cope with inadvertent intraoperative
schemia-reperfusion injury is becoming more prevalent3
It is widely established experimentally that long-chain
mega-3 fatty acids protect against and can terminate isch-
mic ventricular arrhythmias.4,5 Their anti-inflammatory ef-
ects, which include attenuation of leukocyte-endothelial
nteractions and production of less biologically active pros-
aglandins and leukotrienes, could also be beneficial in
ardiac ischemia-reperfusion injury. Previous observations
ave shown that omega-3 pretreatment induces heat shock
roteins (HSP) in the brain, protecting against cerebral
nfarction, suggesting a preconditioning phenomenon.6 We
ought to delineate whether a long-chain omega-3 fatty acid
nfusion normally used as part of parenteral nutrition, and so
pproved for clinical use, might confer myocardial protec-
ion when administered in the acute setting. In eliciting the
ossible mechanism of any observed protection, we focused
n the effects of incorporating the fatty acids into the
yocardial membrane, a process shown to be important in
heir antiarrhythmic effect.5 We further hypothesized tha
nhanced levels within the membrane would favorably alter
he pattern of myocardial membrane oxidant ischemia-
eperfusion injury. The presence of a preconditioning effect
as also studied through measurement of HSP72 levels.
aterials and Methods
ll animal experiments were performed under a license obtained
rom the Department of Health of Ireland under the Cruelty to
nimals Act of 1876. The protocol was approved by the animal
esearch ethics committee of The Royal College of Surgeons in
reland. Animal care was conducted in conformity with institu-
ional guidelines in compliance with international laws and
Abbreviations and Acronyms
HSP  heat shock protein
LVEDP  left ventricular end-diastolic pressure
LVESP  left ventricular end-systolic pressure
dP/dtmax maximum rate of change of systolic and
diastolic pressures
dP/dtmin minimum rate of change of systolic and
diastolic pressuresolicies. 3
The Journal of Thoracxperimental Procedure
ale New Zealand White rabbits (weight 2.5-3.5 kg) were accli-
ated in a quarantine room with access to standard pellet diet and
ater ad libitum for 10 days without any stresses. Rabbits were
ssigned alternatively (n  14 in each group) to receive either an
icosapentanoic acid–docosahexanoic acid lipid emulsion ap-
roved for clinical use as part of parenteral nutrition (Omegaven;
resenius Kabi, Bad Homburg, Germany) at a dose of 5 mL/kg or
n equal volume of 0.9% saline. The infusion was given daily for
days over 4 hours and again 2 hours before the procedure via the
arginal ear vein. The anesthetized in situ rabbit model of regional
ardiac ischemia-reperfusion injury was used as described previ-
usly.7 In brief, anesthetized rabbits (ketamine 35 mg/kg 
ylazine 5 mg/kg) were ventilated via a tracheostomy (100%
xygen, isoflurane 2 L/min) maintaining a PCO2 less than 4.0 kPa.
2.2F Millar cardiac catheter (SPR-249A; Millar Instruments,
nc, Houston, Tex) was in the left carotid artery for hemodynamic
easurements and a 20-gauge cannula in the left external jugular
ein for blood sampling, with a temperature of 38.5°C  0.5°C.
fter left anterolateral thoracotomy, the large marginal branch of
he left coronary artery was occluded for 30 minutes and reper-
used for 3 hours. Further rabbits (n  5 in each group) underwent
nfusions, planned death under anesthesia, and cardiac excision.
hese hearts were preserved for immunohistochemistry and for
easurement of myocardial membrane fatty acid composition and
SP72.
Evaluation of infarct size. After 3 hours of reperfusion the
xcised heart was mounted on a modified Langendorff appara-
us, snare reoccluded, and infused with 0.5% copper phthalo-
yanine dye (Sigma-Aldrich, UK, Poole, Dorset, United King-
om) to determine the volume “at risk” of infarction. The heart
as cut into 2-mm thick slices and stained with 1% triphenyl-
etrazolium dye (Sigma-Aldrich, UK) to determine the infarcted
olume. At both stages the slices were scanned into a com
nd “at-risk” and infarct measurements were performed with
cion Image software (Microsoft Corporation, Redmond,
ash). Results were reported as the percentage of the “at-risk”
olume infarcted for each heart.7
Hemodynamic measurements. Hemodynamic recordings were
rocessed with PowerLab 2/20 (ADInstruments, Oxfordshire, UK)
nd Chart v4.04. The catheter was temporarily advanced into the
eft ventricle before thoracotomy and at 3 hours of reperfusion.
he left ventricular end-diastolic (LVEDP) and end-systolic
LVESP) pressures and the maximum and minimum rates of
hange of systolic and diastolic pressures (dP/dtmax and dP/dtmin),
easures of left ventricular function, were assessed.
Quantification of myocardial membrane fatty acid composi-
ion. Myocardial membrane fatty acid composition was assessed
y high-performance capillary gas chromatography. In brief, a
50-mg heart sample was homogenized in 1 mL of methanol
ontaining 75 g/mL of undecanoic acid. Contents were vortex
ixed, then 2 mL of chloroform was added, and the contents were
ortex mixed again. This was followed by the addition of 1 mL of
% potassium chloride solution, vortex mixed, contents centri-
uged, and the lower lipid containing layer removed and evapo-
ated to near dryness. The extract was reconstituted in 3 mL of
ethanol saturated with sodium hydroxide and heated at 70°C for0 minutes. Then 4 mL of a 14% boron trifluoride in methanol
ic and Cardiovascular Surgery ● Volume 132, Number 1 73
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CSPolution was added and further heated at 70°C for 20 minutes.
ext, 15 mL of deionized water was added and the contents were
llowed to cool. The resultant methyl esters were extracted into 1
L of hexane and dried over anhydrous sodium sulfate. All
eagents were from VWR International (UK). One microliter of
ach sample was injected into a Shimadzu GC-17AAF gas chro-
atograph (Shimadzu, Kyoto, Japan). Relative concentrations of
he 28 fatty acids that compose the myocardial membrane were
eported as percentage of the total myocardial membrane fatty
cids.
Measurement of membrane fatty acid oxidation products.
enous blood samples were taken at baseline, 15 minutes, and 3
ours of reperfusion for measurement of membrane fatty acid
xidation products liberated into the circulation during reperfusion
s markers of myocardial cell membrane injury. Malonaldehyde, a
arker of general polyunsaturated fatty acid oxidation including
mega-3 fatty acids, was assessed in plasma samples with a
alorimetric assay (437634; Merck Biosciences, UK, Nottingham,
nited Kingdom), as described previously.8 Membrane arachi-
onic acid oxidation liberates 8-isoprostane into the circula
uring early reperfusion.9 For 8-isoprostane levels, serum sampl
nderwent affinity purification (516358; Cayman Chemical, A
rbor, Mich) and then measurement of 8-isoprostane with the
tat-8-Isoprostane ELISA kit (500431; Cayman Chemical).
Measurement of HSP72 by Western blotting. Myocardial
SP72 levels were examined by Western blotting. In brief, left
entricular samples were thawed, homogenized in cold phosphate-
uffered saline solution, centrifuged, supernatants were collected, and
rotein concentrations were measured with the bicinchoninic acid
rotein concentration assay (23227; Pierce Biotechnology, Rockford,
ll). Thirty micrograms of each sample in loading buffer (0.6 mmol/L
ris-HCl, pH 6.8, 2% sodium dodecylsulfate, 5% 2-mercaptoethanol,
0% glycerol, 0.01% bromophenol blue) was separated by electro-
horesis on a 12% sodium dodecylsulfate gel. Proteins were trans-
erred electrophoretically to nitrocellulose membrane (66485; Pall
ife Sciences, East Hills, NY) overnight. The membrane was incu-
ated in 6% nonfat dried milk and 0.2% Tween-20 (BDH Laboratory
upplies, Poole, Dorset, United Kingdom) in phosphate-buffered sa-
ine solution, followed by incubation with 1:1000 mouse antihuman
SP72 antibody (SPA-810; Stressgen Biotechnologies Corporation,
an Diego, Calif), then 1:2000 horseradish peroxidase-conjugated
oat antimouse antibody (SAB-100; Stressgen), and developed with
he enhanced chemiluminescence system (34075; Pierce Biotechnol-
gy). The membranes were subsequently exposed to stripping solu-
ion (0.2 mol/L glycine, 0.1% sodium dodecylsulfate, 1% Tween, pH
.2) and reprobed with a 1:20,000 dilution of mouse antirabbit beta-
ctin antibody and a 1:2000 dilution of secondary antibody as before.
he developed films were scanned into a computer for densitometry
ssessment of band intensity, with normalization of HSP72 values
ith beta-actin used for statistical comparison with controls.
Immunohistochemistry. The samples of left ventricle were cut
nto 4-m sections, deparaffinized, and stained with standard
ematoxylin and eosin to assess for any acute inflammation or
tructural changes in the myocardium after pretreatment. Immu-
ohistochemistry was also performed to identify any changes in
acrophage content in the pretreated myocardium. Sections were
ncubated in 1X Trilogy solution (Cell Marque Corp, Hot Springs,
rk) in a pressure cooker for dewaxing, rehydration, and antigen r
4 The Journal of Thoracic and Cardiovascular Surgery ● July 2etrieval. The DAKO Envision System was used for processing
Dako Cytomation, Carpinteria, Calif). In brief, endogenous per-
xidase activity was blocked, tissue sections were probed with
:100 dilution of mouse antihuman macrophage antibody
MCA874G; Serotec UK, Kidlington, Oxford, United Kingdom),
hen labeled with horseradish peroxidase polymer antibody, ex-
osed to 3-3=diaminobenzadine substrate chromagen, and counter-
tained with hematoxylin. Rabbit spleen was used as a positive
ontrol.
Statistical analysis. Results are expressed as means  stan-
ard error of the mean. Infarct and “at-risk” volumes were ana-
yzed with a Student t test. Hemodynamic data were analyzed by
2-way classification analysis of variance. Mechanism data were
nalyzed with a 1-way analysis of variance, with post-hoc com-
arisons performed using the Bonferroni comparison of means as
ppropriate.
esults
eduction of Infarct Size
verall, there was approximately a 40% reduction in infarct
ize in the omega-3 pretreated group (P  .01). The “at-
isk” volumes were similar in both groups (0.78 0.05 cm3
n the control group vs 0.82  0.05 cm3 in the omega-3
roup, P  .7), making them comparable, but the percent-
ge infarction of the “at-risk” area was significantly less in
he omega-3 pretreated group (29.1%  1.9%) than that in
he control group (50.4%  2.1%, P  .01).
hanges in Left Ventricular Function
hroughout the ischemia-reperfusion period there was no
ignificant difference in hemodynamics, with LVESP (54.1
2.1 mm Hg in the control group vs 56.3  0.8 mm Hg in
he omega-3 group, P  .46) and left ventricular function
dP/dtmax 1688 105 mm Hg/s in the control group vs 1562
53 mmHg/s in the omega-3 group, P  .38, and dP/dtmin
1717  81 mmHg/s in the control group vs 1681  56
m Hg/s in the omega-3 group, P  .7) comparable after 3
ours of reperfusion (Table 1). The fact that there w
ifference in hemodynamics outruled this as a confounding
actor that may have influenced infarct size as a result of
ifferences in cardiac perfusion. Also, the lack of an early
mprovement in hemodynamics despite significant reduc-
ion in infarct size has previously been demonstrated with
his model.10 After the omega-3 infusion, a small but -
ificant amount of diastolic dysfunction was seen before
horacotomy. This was evidenced by an increase in LVEDP
1.0  0.5 mm Hg in the control group vs 4.4  0.8 mm Hg
n the omega-3 group, P  .01) and a decrease in diastolic
unction (dP/dtmin 3146  78 mm Hg/s in the control
roup vs 2532  146 mm Hg/s in the omega-3 group, P
 .01), which persisted during reperfusion (Table 1).
hanges in HSP72 Levels
o assess whether the natural endogenous protective stressesponse, that is, the phenomenon of preconditioning, was
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Pnvolved in the protection afforded by the omega-3 pretreat-
ent, we looked at changes in myocardial HSP72 levels
fter pretreatment but before ischemia-reperfusion.11 West-
rn blot assessment showed that HSP72 levels were 225%
igher in the omega-3 pretreated group than in controls (P
 .019, Figure 1).
ltered Composition of the Myocardial Membrane
nd Pattern of Membrane Fatty Acid Oxidant Injury
he myocardial membranes of the groups of rabbits pre-
reated with the infusions without undergoing ischemia-
eperfusion (n  10) showed marked specific changes in
heir composition despite only 4 days of pretreatment. Of
he 28 fatty acids that compose the myocardial membrane,
showed significant changes in their relative content. These
ere the two long-chain omega-3 fatty acids. There was a
5-fold increase in eicosapentanoic acid (0.10% 0.02% of
otal membrane fatty acids in the control group vs 1.87% 
.06% in the omega-3 pretreated group, P  0.0001) and a
-fold increase in docosahexanoic acid (0.48%  0.05% of
otal membrane fatty acids in the control group vs 3.52% 
.39% in the omega-3 pretreated group, P  .01) (Figure 2)
espite this, arachidonic acid remained in the same concen-
ration within the membrane (11.01%  1.14% of total
embrane fatty acids in the control group vs 12.44% 
.41% in the omega-3 pretreated group, P  .6) (Figure 2)
alonaldehyde levels, which represent polyunsaturated
atty acid oxidant injury, rose in both groups during reper-
usion but to significantly higher levels in the omega-3
retreated group at 3 hours of reperfusion (6.1  0.7
mol/L in the control group vs 10.2  1.5 mol/L in the
ABLE 1. Left ventricular function during the ischemia-
eperfusion period
Control group Omega-3 group P value
aseline
LVESP (mm Hg) 67.9 1.3 68.7 0.8 0.8
dP/dtmax (mm Hg/s) 2287 68 2287 142 .9
LVEDP (mm Hg) 1.0 0.5 4.4 0.8 .01
dP/dtmin (mm Hg/s) 3146 78 2532 146 .01
fter 3 hours of reperfusion
LVESP (mm Hg) 54.1 2.1 56.3 0.8 .46
dP/dtmax (mm Hg/s) 1688 105 1562 53 .38
LVEDP (mm Hg) 3.5 0.5 8.3 0.8 .01
dP/dtmin (mm Hg/s) 1717 81 1681 56 .7
he reduction in infarct size in the omega-3 pretreated group was not
ssociated with any early improvement in left ventricular function at 3
ours of reperfusion. A small but significant amount of diastolic dysfunc-
ion was present in the omega-3 pretreated group after pretreatment as
ndicated by changes in rate of change of pressure during diastole (dP/
tmin) and left ventricular end-diastolic pressure (LVEDP). LVESP, Left
entricular end-systolic pressure; dP/dtmax, rate of pressure change during
ystole.mega-3 pretreated group, P  .04). In contrast to malon- i
The Journal of Thoracldehyde, at 15 minutes of reperfusion 8-isoprostane levels,
marker of arachidonic acid oxidant injury, were 9-fold
ower in the omega-3 pretreated group (679.1  189.6
g/mL in the control group vs 73.7  44.8 pg/mL in the
mega-3 pretreated group, P  .0077) (Figure 3).
istologic Changes
istologic assessment of the hearts after pretreatment but
ithout ischemia-reperfusion (n  10) showed no inflam-
atory changes after pretreatment, including tissue macro-
hage content. Infrequently but consistently in each heart in
he omega-3 pretreated group, we noted the presence of
mall areas of contraction band necrosis (Figure E1
istologic change seen in the heart under conditions of
tress.
iscussion
ith increasing complexity of adult and pediatric cardiac
urgical procedures, complete myocardial protection is
roving challenging. Attempts to provide additive cardio-
rotection to date have met with little benefit in clinical
rials. Most new therapies, such as the sodium/hydrogen
xchange inhibitors or leukocyte depletion of cardioplegic
olutions, have focused on a single aspect of the pathologic
igure 1. Myocardial heat shock protein 72 (HSP72) levels mea-
ured by Western blot after pretreatment. Relative concentrations
ere standardized with beta-actin levels. A significantly higher
225%) level of HSP72 expression is present in the omega-3
retreated group (P  .019).schemia-reperfusion injury, with minimal benefit. Recent
ic and Cardiovascular Surgery ● Volume 132, Number 1 75
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CSP bservations of a reduction in sudden death both in normal
ealthy individuals and in those who received oral omega-3
atty acids after a myocardial infarct suggested that there
ay be a conserved natural phenomenon of protection
gainst arrhythmias associated with higher omega-3 fatty
cid levels.12,13 Confirmation of an antiarrhythmic effect 
nimal models and delineation of the mechanism in isolated
ardiomyocytes pointed to the common essential fact that
he additional omega-3 fatty acids reside either partitioned
r incorporated into the myocardial cell membrane to me-
iate their effect.14 We hypothesized that acute intrav-
ous pretreatment with omega-3 fatty acids might rapidly
llow their incorporation into the myocardial membrane
o provide anti-infarct protection through a dual effect:
rotection of the intracellular environment through in-
uction of a natural HSP stress response (that is, precon-
itioning) and protection of the cell membrane against
xidant reperfusion injury through the changes in mem-
rane composition. We used the in situ rabbit model of
egional cardiac ischemia-reperfusion injury to assess the
otential to attenuate infarct development. This model
as been used widely to examine potential cardiac pre-
onditioning agents and to assess the mechanism of pro-
ection with preconditioning.7
This study demonstrates for the first time that a
ntravenous supplementation with an omega-3 emulsion,
hich is normally used as part of parenteral nutrition regi-
ens, is associated with a significant reduction in myocar-
ial ischemia-reperfusion injury. This protection is pre-
eded by an upregulation of HSP72 in the heart in response
Figure 2. Eicosapentanoic acid, docosahexanoic acid,
membrane after pretreatment, expressed as a percento omega-3 pretreatment. HSPs function as molecular chap- w
6 The Journal of Thoracic and Cardiovascular Surgery ● July 2rones in all cells, guiding the folding of newly formed
roteins, maintaining protein conformation, and enhancing
he elimination of damaged proteins to prevent their toxic
ccumulation.11 HSP induction has been used as a marke
nduction of the phenomenon of preconditioning, wh
xposure to a nonlethal stimulus activates the natural en-
ogenous cellular stress response to protect against a sub-
equent more lethal injury. The finding of higher HSP72
evels in the heart in response to omega-3 pretreatment and
he subsequent reduction in infarct size in this study is
upported by previous studies demonstrating a direct corre-
ation between the amount of HSPs induced (particularily
SP72) and the degree of myocardial protection (r  0.97,
  .37).11 Intriguing relationships between precondition-
ng and the omega-3 content of the cell membrane have
een suggested. Increased omega-3 content in the cell mem-
rane reduces myocardial oxygen demand and attenuates
cidosis and lactate accumulation in the ischemic hea15
schemic preconditioning actually increases the content of
he omega-3 fatty acid docosahexanoic acid in the myocar-
ial membrane in advance of a further injury.16 Also similar
o our findings, thermal preconditioning 24 hours in ad-
ance of cardiac ischemia-reperfusion injury produces
ower circulating levels of arachidonic acid and improved
unctional recovery, again illustrating that enhanced mem-
rane stability during reperfusion is a key mediator of
reconditioning cardioprotection,17 as suggested in th
tudy. Although induction of HSP72 in this study was
ssociated with a reduction in infarct size, it did not improve
arly hemodynamic recovery from ischemic injury, a
rachidonic acid concentrations in the myocardial cell
f total membrane fatty acid content.and a
age oidely described observation with ischemic precondition-
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Png. Therefore, to delineate whether pretreatment is activat-
ng preconditioning, further work is ongoing to assess other
spects involved in preconditioning protection, such as the
ctivation state of the inflammatory transcription factor
uclear factor kappa B, and measurement of other proteins
uch as cyclooxygenase-2 and inducible nitric oxide syn-
hase, known to be upregulated by preconditioning.
We also found that the protection was preceded by a
igure 3. Malonaldehyde levels, a marker of polyunsaturated
atty acid oxidant injury, rose as is normal during reperfusion but
ere higher in the omega-3 pretreated group at 3 hours of
eperfusion (P  .04). Conversely, 8-isoprostane levels, a marker
f arachidonic acid oxidant injury, were 9 times lower in the
mega-3 pretreated group during reperfusion (P  .0077).ignificant increase in the omega-3 content of the cell mem- t
The Journal of Thoracrane and subsequently changes in the pattern of oxidant
eperfusion injury; that is, an increase in the amount of
olyunsaturated fatty acid oxidation (malonaldehyde levels)
nd a marked reduction in the amount of arachidonic acid
xidation (8-isoprostane levels). This suggests a shift in the
xidant injury away from arachidonic acid, which is struc-
urally and functionally important to the myocardial mem-
rane, and instead toward polyunsaturated fatty acids such
s the additional omega-3 fatty acids that have partitioned
nto the membrane. Polyunsaturation within a fatty acid
efers to the number of double bonds within the fatty acid.
he more double bonds a fatty acid has, the more readily it
s oxidized. Of the 28 fatty acids that compose the myocar-
ial membrane, the omega-3 fatty acids, eicosapentaneoic
cid and docosahexaneoic acid, have 5 and 6 double bonds
espectively, making them the most polyunsaturated mole-
ules within the membrane. Arachidonic acid has only 4
ouble bonds, so it is likely that the additional omega-3 fatty
cids that have been incorporated into the membrane as a
esult of pretreatment will be preferentially oxidized over
rachidonic acid. Additionally, the majority of the 28 fatty
cids that compose the membrane are relatively unsaturated.
much larger quantity would be required to absorb a given
xidant injury, whereas only a smaller quantity of highly
olyunsaturated fatty acids would be needed to absorb the
ame oxidant injury owing to the greater amount of double
onds in the polyunsaturated fatty acids. It may be that by
ncreasing the omega-3 fatty acid content of the myocardial
embrane, we not only protect against arachidonic acid
xidant injury but also likely limit the overall degree of
embrane injury by, in effect “mopping-up” the excessive
eactive oxygen species during reperfusion.
It is widely known that oxidant damage to the heart is
losely linked to cardiac dysfunction.18 In this study, ma-
naldehyde levels are higher in the omega-3 pretreated
roup during reperfusion, but 8-isoprostane levels are
ower, indicating less arachidonic acid oxidation. Lipid hy-
roperoxides from arachidonic acid oxidation cause loss of
ardiomyocyte membrane integrity, electromechanical al-
erations, and enzyme leakage, leading to cell destructio19
rachidonic acid supplementation has previously been
hown to enhance reactive oxygen radical injury to neonatal
at cardiac myocytes.20
The enhanced omega-3 content of the myocardial mem-
ranes that we observed may also confer other well-established
eneficial traits for ischemic myocardium. Prolonged oral
upplementation with omega-3 fatty acids produces similar
yocardial membrane fatty acid changes to those seen in
ur study, which are associated with reduced myocardial
xygen consumption and increased coronary perfusion re-
erve; after ischemia, creatine kinase, lactate, and acidosis
ithin the heart are reduced, with improvements in contrac-ile recovery during reperfusion.15 When rats are supple-
ic and Cardiovascular Surgery ● Volume 132, Number 1 77
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CSPented for 8 weeks with oral omega-3 fatty acids, there is
 reduction in infarct size of 48%, similar to our findi21
his benefit is seen only after 8 weeks of oral supplmenta-
ion, as oral supplmentation for a single week does not
roduce any reduction in infarct size.21 Acute intravenous
upplementation may be able to circumvent this manda
ong pretreatment period, as our study suggests.
The presence of contraction band necrosis and mild
iastolic dysfunction in this study after pretreatment also
uggests that a stress response has been induced within the
eart. The phenomenon of contraction band necrosis and
ssociated myocardial dysfunction has been shown to be a
ransient effect not apparently associated with further dele-
erious consequences.22
This study has some limitations, particularly related to
he use of a regional myocardial ischemia-reperfusion injury
odel. The reduction in infarct size was not associated with
mprovements in hemodynamics at 3 hours of reperfusion, a
nding that has previously been demonstrated in this model
ith ischemic preconditioning,10 although it is widel
nown in other experimental models that ischemic precon-
itioning improves functional recovery. This initial study
as to investigate whether intravenous short pretreatment
ith omega-3 fatty acids could protect against infarction.
learly, a 4-day pretreatment period is not clinically rele-
ant, but this prolonged pretreatment was chosen to ensure
ncorporation of omega-3 into the myocardial membrane.
he marked increase in eicosapentanoic and docosahex-
noic acid levels in the membrane that we observed suggest
hat a shorter pretreatment period may also be effective.
inally, although this model more likely parallels myocar-
ial injury in off-pump surgery, the mechanism of protec-
ion would clearly be additional to cardioplegia, but further
tudies using a global myocardial ischemic model with
ardioplegic arrest are necessary to define this further.
Patients with a more limited physiologic reserve are
articularly vulnerable to any further small diminution in
ardiac function as an inadvertent consequence of the op-
rative process. This study shows that an omega-3 emulsion
hould not be considered only as a nutritional supplement
ut also as a potentially clinically safe cardioprotective
gent that may act in part through pharmacologic induction
f preconditioning and modulation of myocardial cell mem-
rane structure and function. This strategy warrants further
nvestigation with optimization and shortening of pretreat-
ent regimens to be more clinically applicable.
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iscussion
r Vivek Rao (Toronto, Ontario, Canada). Thank you, Dr
cGuinness, for quite an exhaustive presentation of a lot of data.
would like to summarize some of your findings for the benefit of
he audience, as you allowed me to read your manuscript as well
s to hear your presentation.
You found that a preliminary administration of omega-3 fatty
cids resulted in improvement in the membrane composition of
hese important molecules, which led to protection against infarc-
ion in a regional model of ischemia-reperfusion. Interestingly, you
id not find significant differences in left ventricular function. I
ill come back to that in my questions to you.
You also postulate that the mechanism of benefit is stabilization
f membrane fatty acids, preventing oxidant injury and therefore
eading to preservation model of ischemia-reperfusion.
I have several questions for you.
In the past, several antioxidant-type strategies have looked at
rotection during ischemia-reperfusion both in a regional and a
lobal ischemic model. Although several of these strategies have
een proven to be beneficial, very few have been actually used
linically. I’d like you to comment on the feasibility of clinical
pplication in the type of patients in whom we probably want to
se this strategy, that is, our high-risk, urgent patients in the setting
f an acute infarct. Is it feasible to give them a 4-day pretreatment
f omega-3 or does this require further investigations into the
ubcellular mechanism of action.
Second, you implicate a preconditioning-type phenomenon
n this process with the upregulation of HSP. Can you again
escribe to us how you interrelate a preconditioning-type effect
ith omega-3?
Last, we all know that the heart is an omnivore: it will eat
nything that you give it. What you have not actually shown us in
his study is how the administration of a fatty acid composition
lters normal homeostasis in myocardial energy metabolism. Did
ou inhibit normal glucose oxidation during reperfusion and
hereby lose the benefits of aerobic metabolism on ventricular
unction?
Dr McGuinness. Thank you for your comments.
First of all, yes, certainly many antioxidants have been de-
cribed as being potentially beneficial but in the clinical scenario
ave been absolutely useless. In this case we have shown an
ntioxidant’s beneficial effect. However, I think that the effect of
mega-3 lies much more beyond an antioxidant effect. To say yes, e
The Journal of Thorachis is an antioxidant effect, this is how it’s going to work, is very
implistic.
Omega-3 fatty acids have multiple actions. They have been
nown to be antiarrhythmic. They inhibit leukocyte endothelial
nteractions. They affect prostaglandin and leukotriene production.
s we have shown here, they may have antioxidant effects, and
hey may act in a preconditioning manner. So by giving this
nfusion, we are not looking at one particular aspect. But the
dvantage of it is that we are looking at multimodal therapy for a
articular type of injury.
In regard to the fact that we did not actually show any im-
rovements in hemodynamics in response to the omega-3 infusion,
lthough there was a reduction in infarct size, we were not actually
urprised to see this at all. This open chest rabbit model is the
ell-established model that is used by Dr Bolli’s and Dr Downey’s
roups in the investigation of preconditioning with cardiac
schemia-reperfusion injury. It is widely known, and Dr Downey
as written a paper on this, that although ischemic-preconditioning
oes result in early infarct reduction at 3 hours of reperfusion,
here is no functional improvement within the heart at this early
-hour reperfusion phase. This is probably due to a stunning effect
ithin the heart. So it is perhaps too early to see hemodynamic
enefits.
When you evaluate survival models in which you use the same
abbit model, but you keep the animal alive out to about 6 weeks
nd do echoes and measure ejection fraction, you do actually see
mprovements in ejection fraction and so on at that stage corre-
ponding to the reduction in infarct size. Therein lies the benefit.
The other question concerned the potential for HSP induction
nd how that feeds into omega-3 fatty acids. A number of studies
ith long-term oral supplementation with omega-3 fatty acids
ave been conducted. To get the kind of changes in membrane
atty acid content that we’ve shown here takes 8 to 16 weeks with
ral supplementation. That’s the advantage of using it intrave-
ously.
In rat studies, supplements have been used for that period of
ime and then hemodynamic studies have been conducted. These
ave shown that by pretreating and increasing the omega-3 content
ithin the cell membrane, you reduce myocardial oxygen con-
umption, you improve the coronary perfusion reserve, and you
nduce a kind of hibernation-type state within the heart, which
reconditioning has been aligned with in recent times. We do plan
o do further studies to look at the activation state of nuclear factor
appa B and other preconditioning factors such as cyclooxygenase
, inducible nitric oxide synthase, and so on. That may further
lucidate the mechanism.
ic and Cardiovascular Surgery ● Volume 132, Number 1 79
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CSPFigure E1. Infrequently but consistently small areas of c
the omega-3 pretreated hearts on hematoxylin-eosin sontraction band necrosis (black arrows) were seen within
taining of the left ventricle.9.e1 The Journal of Thoracic and Cardiovascular Surgery ● July 2006
